If a male client taking statins shows unexplained elevation in serum aspartate, what action might the provider take?

In the context of a male client taking statins who presents with an unexplained elevation in serum aspartate aminotransferase (AST), discontinuing the statin is a prudent step. Statins can sometimes lead to liver enzyme abnormalities, including elevation in AST levels. When a patient experiences such elevations—especially if they are significant or persistent—the recommended approach is to assess the potential liver-related side effects of the statin.

Discontinuing the statin helps to determine if the elevated enzyme levels are indeed related to the medication. If the AST levels return to normal after stopping the statin, it indicates that the drug was likely the cause of the elevation. This action prioritizes patient safety and prevents potential damage to the liver, which can occur with ongoing statin use in the presence of elevated liver enzymes.

Monitoring enzyme levels after discontinuation would be essential, and depending on the outcome and clinical judgment, the healthcare provider can decide on a future course of action, which may include re-evaluation of statin therapy or considering alternative lipid-lowering agents.